Main Menu

The technology pertains to a novel multivalent peptide tolerogen designed for the therapeutic treatment of Multiple Sclerosis (MS), a condition where the immune system erroneously attacks the central nervous system. This advanced therapeutic strategy involves a fusion-peptide composed of myelin oligodendrocyte glycoprotein (MOG), myelin-basic protein (MBP), and myelin proteolipid protein (PLP), along with myelin-associated glycoprotein (MAG).

The discovery outlined in the Employee Discovery and Invention Report represents a significant advancement in veterinary vaccine technology, specifically targeting the bovine respiratory syncytial virus (bRSV). This innovation involves a "DS2" version of the bRSV F vaccine, which has been engineered to enhance immunogenicity through a prefusion-stabilized form of the F protein, absent of the fusion peptide and reinforced by cavity-filling mutations and inter-protomer disulfides.

The technology involves a laboratory-derived version of the 2009 pandemic H1N1 virus, produced under Good Manufacturing Practices (GMP) to ensure safety and reproducibility for human studies. It's designed for use in controlled research settings to advance our understanding of influenza pathogenesis and to assess the efficacy of vaccines and drugs.

The PSY2 Bovidae aurbeta/gamma shuttle vector represents a pioneering technology in the field of genetic engineering. This innovative vector system has been designed for use in Bovidae species, potentially offering a novel approach to gene delivery and manipulation. It leverages a dual-functionality mechanism that could enable both autonomous replication and the precise insertion of genetic material.

The "Adjuvant pro-drug platform for gene delivery and spatiotemporal control over immune activation" is a groundbreaking technology that addresses the limitations of DNA and RNA-based vaccines by providing spatiotemporal control over immune activation. This platform utilizes a cationic polymer with pro-drug Toll-like receptor-7/8 agonists attached, allowing for the complexation of RNA and DNA to form nanoparticles for in vivo administration.

This technology presents innovative methods for manufacturing peptide-based vaccines that effectively induce T cell responses. By linking peptide antigens to adjuvants with hydrophobic blocks, a conjugate vaccine is created that self-assembles into nanoparticles, also known as immunotherapeutic nanoscaffolds (IMNs).

The discovery of RPS3 and phospho-RPS3 antibodies represents a significant advancement in understanding mammalian gene regulation and its implications for disease. These antibodies serve as critical tools for detecting and studying the NF-kB transcription factor, particularly its specifier subunit RPS3 and its phosphorylated form.

The discovery involves the development and characterization of a novel SHIVAD8EO virus, which has significant implications for HIV/AIDS research and therapy development. This virus, when propagated in DH101 cells and used to infect rhesus PBMC, exhibits efficient replicative properties and utilizes CCR5 to enter monkey cells. Importantly, the virus displays a tier 2 neutralization phenotype similar to circulating HIV-1 strains.

In this groundbreaking approach, a versatile AIDS vaccine technology is tailored to target distinct HIV clades prevalent in different regions, including Clade B for the United States, Clade AG for West Africa, and Clade C for South Africa and India. The vaccine serves a dual purpose, functioning both as a prophylactic and therapeutic solution against HIV/AIDS. Furthermore, it can be employed in synergy with DNA vaccines and the immune-boosting properties of GM-CSF to enhance the immune response.

The document details the creation of an anti-idiotypic monoclonal antibody specifically targeting the PGT121 monoclonal antibody (mAb) used in HIV treatment, highlighting its potential in both therapeutic and preventative applications. To ensure the consistent quality and effectiveness of the PGT121 mAb, these anti-idiotypic antibodies are developed for monitoring purposes during clinical applications.